Exchanged 246,667 Exchange Warrants for 74,000 shares of Common Stock in the warrant exchange offer.
| Officer | Age | In this role | 2025 pay | Source |
|---|---|---|---|---|
|
Mary Szela
Also a director
Chief Executive Officer, President and Director
|
62 | Not stated | $4,823,349 | |
|
David Patience
Chief Financial Officer
|
40 |
Since 2025
1 year
|
$3,443,628 | |
|
Jennifer Stevens
Chief Regulatory Officer
Title from the Form 4 dated Oct 5, 2026
|
65 | Not stated | Not reported | |
|
Richard Marshak
Chief Commercial Officer
|
67 |
Since 2025
1 year
|
$1,556,000 | |
|
Richard Marshall
Chief Medical Officer
Title from the Form 8-K dated Jun 29, 2026
|
Not stated | Not stated | Not reported | |
|
Bryan Cox
Chief of Research
|
64 |
Since 2020
6 years
|
Not reported |
Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.
Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.
Exchanged 246,667 Exchange Warrants for 74,000 shares of Common Stock in the warrant exchange offer.
Purchased 62,972 shares of Common Stock in the December 2024 private placement.
Purchased 50,377 shares of Common Stock in the December 2024 private placement.
Purchased 25,188 shares of Common Stock in the December 2024 private placement.
Purchased 200,000 shares of Common Stock in the April 2025 private placement.
Purchased 62,500 shares of Common Stock in the April 2025 private placement.
Loading...